Multi-omics Approaches Identify Uremic Toxins and Immune Regulators as Circulating Biomarkers of Metastatic RCC
KIDNEY CANCER JOURNAL, 2026
Ornstein M., Ye X., Dutta S., Varadharajan V., Wei W., Lamenza M., Patel M., Diaz-Montero M., Brown M., Chakraborty A.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Oncology Nephrology | Patient Stratification | Plasma | Olink Target 96 |
Abstract
BACKGROUND: The diagnosis and treatment of metastatic renal cell carcinoma (mRCC) is challenging. Drug combinations targeting the immune checkpoint and angiogenesis have improved clinical outcomes. However, non-invasive diagnostic and prognostic biomarkers of mRCC are lacking.RESULTS: Using plasma samples from 56 RCC patients (n=22 localized versus n=34 metastatic disease), we leveraged two recent methods: (1) high-throughput proteomics and (2) gut microbiome-focused targeted metabolomics, fornon-invasive biomarker identification of localized vs mRCC (Two-sample t-tests: FDR<20% and p<0.027). Elevated biomarkers in mRCC included soluble PD-L1 (sPD-L1, p<0.0001) and CLMP (p=0.002), as determined by proteomics; and indole (p<0.0001), 5-hydroxy-indole acetic acid (5-HIAA, p=0.002), and phenylacetylglutamine (PAGln, p=0.005), as determined by microbial metabolomics.CONCLUSIONS: sPD-L1, indole derivatives, and PAGln, which have links to immune regulation and nephric integrity, were identified as biomarkers of mRCC. Follow-up studies with larger cohorts will address the oncogenic mechanisms and relevance of these biomarkers in therapy response.